Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|January 5, 2025
[The Potential Analysis of Flavoring Agents as Novel Functional Foods]Takuya Yamashita, Kazuya Nagano
Optics Express|January 26, 2012
Selection of optimal combinations of band-pass filters for ice detection by hyperspectral imagingShigeki Nakauchi, Ken Nishino, Takuya Yamashita
Biological & Pharmaceutical Bulletin|November 1, 2023
Extracellular Vesicles Derived from the Serum of Seriola quinqueradiata Induce Human Umbilical Vein Endothelial Cell Proliferation through Angiogenic SignalingTakuya Yamashita, Ryotaro Tsutsumi, Kazuya Nagano
Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry|December 24, 2019
Synergistic Ion-pair Extraction and Separation of Trivalent Lanthanoid Ions with 4-Isopropyltropolone and 1,10-Phenanthroline into o-DichlorobenzeneTakuya Yamashita, Yoshio Nishiyama, Kotaro Morita, et al.
Journal of Pharmacological Sciences|April 25, 2014
Involvement of the long-chain fatty acid receptor GPR40 in depression-related behaviorTakashi Nishinaka, Takuya Yamashita, Kazuo Nakamoto, et al.
CEN Case Reports|May 17, 2017
An autopsy case that manifested no convincing histological changes of severe renal failure after hematopoietic stem cell transplantationKosuke Honda, Minoru Ando, Masaharu Tsubokura, et al.
Platelets|October 15, 2010
Eight-year follow-up of patients with immune thrombocytopenic purpura related toH. pyloriinfectionTaku Kikuchi, Takeshi Kobayashi, Takuya Yamashita, et al.
Internal Medicine (Tokyo, Japan)|May 15, 2010
Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoringShihoko Wakabayashi, Kazuteru Ohashi, Ryo Hanajiri, et al.
International Journal of Hematology|March 2, 2010
Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phaseYasunobu Nagata, Shiomi Fukuda, Takeshi Kobayashi, et al.
Molecular and Clinical Oncology|August 8, 2017
Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinomaNobuki Furubayashi, Takahito Negishi, Takuya Yamashita, et al.
Pageof 11